A Study to Investigate the Effect of Ciclosporin on the Pharmacokinetics of Baricitinib (LY3009104) in Healthy Subjects

Trial Profile

A Study to Investigate the Effect of Ciclosporin on the Pharmacokinetics of Baricitinib (LY3009104) in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Baricitinib (Primary) ; Ciclosporin
  • Indications Diabetic nephropathies; Psoriasis; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 08 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Oct 2013 New trial record
    • 01 Oct 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top